Veterinary vaccines against Toxoplasma gondii

Innes, Elisabeth A.; Bartley, Paul M.; Maley, S.W.; Katzer, Frank; Buxton, D.

doi:10.1590/s0074-02762009000200018

Cited by 81 publications

(64 citation statements)

References 57 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…nanoparticle | vaccine platform | replicon | viruses | parasites T oday, there are a range of vaccine technologies used clinically, with varied use of inactivated pathogens, molecular antigens, adjuvants, delivery technologies, administration routes, and dosing regimes (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13). Although existing vaccine systems have had a huge impact on prevention of infectious disease, challenges remain.…”

mentioning

confidence: 99%

Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose

Chahal

Khan

Cooper

et al. 2016

Proc. Natl. Acad. Sci. U.S.A.

337

260

View full text Add to dashboard Cite

Vaccines have had broad medical impact, but existing vaccine technologies and production methods are limited in their ability to respond rapidly to evolving and emerging pathogens, or sudden outbreaks. Here, we develop a rapid-response, fully synthetic, single-dose, adjuvant-free dendrimer nanoparticle vaccine platform wherein antigens are encoded by encapsulated mRNA replicons. To our knowledge, this system is the first capable of generating protective immunity against a broad spectrum of lethal pathogen challenges, including H1N1 influenza, Toxoplasma gondii, and Ebola virus. The vaccine can be formed with multiple antigen-expressing replicons, and is capable of eliciting both CD8+ T-cell and antibody responses. The ability to generate viable, contaminant-free vaccines within days, to single or multiple antigens, may have broad utility for a range of diseases.

show abstract

mentioning

confidence: 99%

Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose

Chahal

Khan

Cooper

et al. 2016

Proc. Natl. Acad. Sci. U.S.A.

337

260

View full text Add to dashboard Cite

show abstract

“…The T-263 strain of T. gondii is a live mutant strain designed to reduce or prevent oocyst shedding by cats by developing only partially in the feline intestinal tract [25]. Field trials with this feline vaccine were conducted on US pig farms [25,26]. Cats were trapped, vaccinated, and released.…”

Section: Prevention Of Infection In Cats and Humansmentioning

confidence: 99%

“…Cats were trapped, vaccinated, and released. Following the vaccination of the resident cats on the farms, T. gondii seroprevalence in the farmed pigs decreased, suggesting less environmental contamination with oocysts, and thus, less infection risk for the pigs [25,26]. There are reports of attempted vaccination of cats using T. gondii strains modified by irradiation, chemical treatments, selected recombinant antigens, and new delivery systems, including a feline herpes-virus type 1 vehicle for delivery.…”

Section: Prevention Of Infection In Cats and Humansmentioning

confidence: 99%

Toxoplasma gondii: epidemiology, feline clinical aspects, and prevention

Elmore

Jones

Conrad

et al. 2010

Trends in Parasitology

411

326

View full text Add to dashboard Cite

“…The development of protective immunity to T. gondii following natural infection in many host species has led researchers to look at vaccination as a strategy to control disease, parasite multiplication and establishment in hosts (Innes et al 2009). …”

Section: Introductionmentioning

confidence: 99%

A comparative study between excretory/secretory and autoclaved vaccines against RH strain of Toxoplasma gondii in murine models

et al. 2013

View full text Add to dashboard Cite

Toxoplasma gondii is an obligate intracellular protozoan that has a major importance in public health, in addition to veterinary medicine. Therefore, the development of an effective vaccine for controlling toxoplasmosis is an important goal. Excretory/secretory antigens (ESA), were previously identified as potential vaccine candidates, proved to play important roles in the pathogenesis and immune escape of the parasite. In addition, autoclaved Toxoplasma vaccine (ATV) is a special type of killed vaccine, recently characterized. The aim of the present work was, to compare between excretory/secretory and ATV against RH strain of T. gondii in mice based on; parasitological and histopathological levels. Tachyzoites were harvested from peritoneal exudates of infected mice and were used for challenge infection and vaccine preparation. BCG was used as an adjuvant. Mice were allocated equally into five groups; they were vaccinated intradermally over the sternum. The results of this study showed that the survival time after challenge, extended up to 16 days in ESA vaccinated group and up to 15 days in autoclaved Toxoplasma vaccinated group. ESA vaccinated group exhibited a profound decrease in parasite load following parasite challenge with a higher percentage of reduction in parasite count in all examined organs than the autoclaved Toxoplasma vaccinated group. The histopathological picture of the liver in both immunized groups, revealed marked reduction in the pathological changes observed as compared to controls, especially in ESA vaccinated group. It was concluded that vaccination with ESA showed more promising results versus ATV, as demonstrated by the survival rate of vaccinated mice, tachyzoites count and histopathological examination.

show abstract

Veterinary vaccines against Toxoplasma gondii

Cited by 81 publications

References 57 publications

Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose

Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose

Toxoplasma gondii: epidemiology, feline clinical aspects, and prevention

A comparative study between excretory/secretory and autoclaved vaccines against RH strain of Toxoplasma gondii in murine models

Contact Info

Product

Resources

About